

SEQUENCE LISTING

<110> Igeneon Krebs-Immuntherapie Forschungs- & Entwickl

<120> Immunogenic Recombinant Antibody

<130> Immunogenic Recombinant AB

<140>

<141>

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 3973

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:mAB 17-1A

<400> 1

```

ataggctagc ctcgagccac caccatgcat cagaccagca tgggcatcaa gatggaatca 60
cagactctgg tcttcatatc catactgctc tggttatatg gagctgatgg gaacattgta 120
atgacccaat ctcccaaate catgtccatg tcagtaggag agaggggtcac cttgacctgc 180
aaggccagtg agaatgtggt tacttatggt tcntgggtatc aacagaaacc agagcagtct 240
cctaaactgc tgatatatgg ggcattccaac cgggtacactg ggggtccnga tcgcttcaca 300
ggcagtggat ctgcaacaga tttcactctg accatcagca gtgtgcaggc tgaagacctt 360
gcagattatc actgtggaca ggggttacagc tatccgtaca cggttcggagg ggggaccaag 420
ctggaaataa aacgggctga tgctgcacca actgtatcca tcttcccacc atccagttag 480
cagttaacat ctggagggtgc ctcagtcgtg tgcttcttga acaacttcta ccccaaagac 540
atcaatgtca agtggaagat tgatggcagt gaacgacaaa atggcgctct gaacagttgg 600
actgatcagg acagcaaaga cagcacctac agcatgagca gcacctcac gttgaccaag 660
gacgagtatg aacgacataa cagctatacc tgtgaggcca ctcaacagac atcaacttca 720
cccatgttca agagcttcaa caggaatgag tgtagagcgc gtggatccgc ccctctccct 780
ccccccccc taacgttact ggccgaagcc gcttgggaata aggcgggtgt gcgtttgtct 840
atatgtgatt ttccaccata ttgccgtctt ttggcaatgt gagggcccg aaacctggcc 900
ctgtcttctt gacgagcatt cctaggggtc tttcccctct cgccaaagga atgcaaggtc 960
tggtgaatgt cgtgaaggaa gcagttcctc tggaagcttc ttgaagacaa acaacgtctg 1020
tagcgaccot ttgcaggcag cggaaccccc cacctggcga caggtgcctc tgcggccaaa 1080
agccacgtgt ataagataca cctgcaaagg cggcacaacc ccagtgccac gttgtgagtt 1140
ggatagttgt ggaaagagtc aaatggctct cctcaagcgt attcaacaag gggctgaagg 1200
atgcccagaa ggtaccccat tgtatgggat ctgatctggg gcctcgggtg acatgcttta 1260
catgtgttta gtcgagggtta aaaaaacgtc taggcccccc gaaccacggg gacgtggttt 1320
tcctttgaaa aacacgatga taatatggcc accaccatgg aatggagcag agtctttatc 1380
tttctcctat cagtaactgc aggtgttcac tcccagggtc agttgcagca gtctggagct 1440

```

```

gagctggtaa ggcctgggac ttcagtgaag gtgtcctgca aggetttctgg atacgccttc 1500
actaattact tgatagagtg ggtaaagcag aggcctggac agggccttga gtggattggg 1560
gtgattaatc ctggaagtgg tggactaac tacaatgaga agttcaaggg caaggcaaca 1620
ctgactgcag acaaatcctc cagcactgcc tacatgcagc tcagcagcct gacatctgat 1680
gactctgcgg tctatttctg tgcaagagat ggtccctggg ttgcttactg gggccaaggg 1740
actctgggtca ctgtctctgc agccaaaaca acagcccat cggtctatcc actggcccct 1800
gtgtgtggag atacaactgg ctctcgggtg actctaggat gcctgggtcaa gggttatttc 1860
cctgagccag tgaccttgac ctggaactct ggatccctgt ccagtgggtg gcacaccttc 1920
ccagctgtcc tgcagtctga cctctacacc ctacagcagc cagtgactgt aacctcgagc 1980
acctggccca gccagtccat cacctgcaat gtggcccacc cggcaagcag caccaagggtg 2040
gacaagaaaa ttgagcccag agggcccaca atcaagccct gtccctccatg caaatgccc 2100
gcacctaac tcttgggtgg accatccgtc ttcattcttc ctccaaagat caaggatgta 2160
ctcatgatct ccctgagccc catagtcaca tgtgtgggtg tggatgtgag cgaggatgac 2220
ccagatgtcc agatcagctg gtttgtgaac aacgtggaag tacacacagc tcagacacaa 2280
acccatagag aggattacaa cagtactctc cgggtgggtca gtgccctccc catccagcac 2340
caggactgga tgagtggcaa ggagttcaaa tgcaagggtca acaacaaaga cctcccagcg 2400
cccatcgaga gaacctctc aaaacccaaa gggtcagtaa gagctccaca ggtatatgtc 2460
ttgcctccac cagaagaaga gatgactaag aaacagggtca ctctgacctg catggtcaca 2520
gacttcatgc ctgaagacat ttacgtggag tggaccaaca acgggaaaac agagctaaac 2580
tacaagaaca ctgaaccagt cctggactct gatggttctt acttcatgta cagcaagctg 2640
agagtggaaa agaagaactg ggtggaaaga aatagctact cctgttcagt ggtccacgag 2700
ggtctgcaca atcaccacac gactaagagc ttctcccgga ctccgggtaa atgagtcgac 2760
acgcgtcgag catgcattct gggcggccaa ttccgcccct ctccctcccc ccccctaac 2820
gttactggcc gaagccgctt ggaataaggc cgggtgtgct ttgtctatat gtgattttcc 2880
accatattgc cgtcttttgg caatgtgagg gcccggaac ctggccctgt cttcttgacg 2940
agcattccta ggggtcttcc cctctcgc aaaggaatgc aaggtctgtt gaatgtcgtg 3000
aaggaagcag ttcctctgga agcttcttga agacaaacaa cgtctgtagc gaccctttgc 3060
aggcagcgga accccccacc tggcgacagg tgccctctgc gccaaaagcc acgtgtataa 3120
gatacacctg caaaggcggc acaaccccag tgccacgttg tgagttggat agttgtggaa 3180
agagtcaaat ggctctcctc aagcgtattc aacaaggggc tgaaggatgc ccagaaggta 3240
ccccattgta tgggatctga tctggggcct cgggtgcacat gctttacatg tgtttagtcg 3300
aggttaaaaa aacgtctagg cccccgaac cacggggagc tggttttcct ttgaaaaaca 3360
cgatgataag cttgccacaa cccgggatcc tctagaccac catggttcga ccattgaact 3420
gcacgtcgc cgtgtcccaa gatatgggga ttggcaagaa cggagacctc ccctggcctc 3480
cgctcaggaa cgagttcaag tacttccaaa gaatgaccac aacctcttca gtggaaggta 3540
aacagaatct ggtgattatg ggtaggaaaa cctggttctc cattcctgag aagaatcgac 3600
ctttaaagga cagaattaat atagttctca gtagagaact caaagaacca ccacgaggag 3660
ctcattttct tgccaaaagt ttggatgatg ccttaagact tattgaacaa ccggaattgg 3720
caagtaaagt agacatggtt tggatagtcg gaggcagttc tgtttaccag gaagccatga 3780
atcaaccagg ccacctcaga ctctttgtga caaggatcat gcaggaattt gaaagtgaca 3840
cgtttttccc agaaattgat ttggggaaat ataaacttct ccagaatac ccaggcgtcc 3900
tctctgaggt ccaggaggaa aaaggcatca agtataagtt tgaagtctac gagaagaaag 3960
actaagcggc cgc

```

3973

<210> 2

<211> 465

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:mAB 17-1A

<400> 2

Met Glu Trp Ser Arg Val Phe Ile Phe Leu Leu Ser Val Thr Ala Gly
 1 5 10 15
 Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg
 20 25 30
 Pro Gly Thr Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ala Phe
 35 40 45
 Thr Asn Tyr Leu Ile Glu Trp Val Lys Gln Arg Pro Gly Gln Gly Leu
 50 55 60
 Glu Trp Ile Gly Val Ile Asn Pro Gly Ser Gly Gly Thr Asn Tyr Asn
 65 70 75 80
 Glu Lys Phe Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser
 85 90 95
 Thr Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Asp Asp Ser Ala Val
 100 105 110
 Tyr Phe Cys Ala Arg Asp Gly Pro Trp Phe Ala Tyr Trp Gly Gln Gly
 115 120 125
 Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Ala Pro Ser Val Tyr
 130 135 140
 Pro Leu Ala Pro Val Cys Gly Asp Thr Thr Gly Ser Ser Val Thr Leu
 145 150 155 160
 Gly Cys Leu Val Lys Gly Tyr Phe Pro Glu Pro Val Thr Leu Thr Trp
 165 170 175
 Asn Ser Gly Ser Leu Ser Ser Gly Val His Thr Phe Pro Ala Val Leu
 180 185 190
 Gln Ser Asp Leu Tyr Thr Leu Ser Ser Ser Val Thr Val Thr Ser Ser
 195 200 205
 Thr Trp Pro Ser Gln Ser Ile Thr Cys Asn Val Ala His Pro Ala Ser
 210 215 220
 Ser Thr Lys Val Asp Lys Lys Ile Glu Pro Arg Gly Pro Thr Ile Lys

[illegible]

<210> 3

<211> 243

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:mAB 17-1A

<400> 3

Met	His	Gln	Thr	Ser	Met	Gly	Ile	Lys	Met	Glu	Ser	Gln	Thr	Leu	Val	1	5	10	15
Phe	Ile	Ser	Ile	Leu	Leu	Trp	Leu	Tyr	Gly	Ala	Asp	Gly	Asn	Ile	Val	20	25	30	
Met	Thr	Gln	Ser	Pro	Lys	Ser	Met	Ser	Met	Ser	Val	Gly	Glu	Arg	Val	35	40	45	
Thr	Leu	Thr	Cys	Lys	Ala	Ser	Glu	Asn	Val	Val	Thr	Tyr	Val	Ser	Trp	50	55	60	
Tyr	Gln	Gln	Lys	Pro	Glu	Gln	Ser	Pro	Lys	Leu	Leu	Ile	Tyr	Gly	Ala	65	70	75	80
Ser	Asn	Arg	Tyr	Thr	Gly	Val	Pro	Asp	Arg	Phe	Thr	Gly	Ser	Gly	Ser	85	90	95	
Ala	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Val	Gln	Ala	Glu	Asp	Leu	100	105	110	
Ala	Asp	Tyr	His	Cys	Gly	Gln	Gly	Tyr	Ser	Tyr	Pro	Tyr	Thr	Phe	Gly	115	120	125	
Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg	Ala	Asp	Ala	Ala	Pro	Thr	Val	130	135	140	
Ser	Ile	Phe	Pro	Pro	Ser	Ser	Glu	Gln	Leu	Thr	Ser	Gly	Gly	Ala	Ser	145	150	155	160
Val	Val	Cys	Phe	Leu	Asn	Asn	Phe	Tyr	Pro	Lys	Asp	Ile	Asn	Val	Lys	165	170	175	
Trp	Lys	Ile	Asp	Gly	Ser	Glu	Arg	Gln	Asn	Gly	Val	Leu	Asn	Ser	Trp	180	185	190	
Thr	Asp	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Met	Ser	Ser	Thr	Leu	195	200	205	

Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu
 210 215 220

Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg
 225 230 235 240

Asn Glu Cys

<210> 4

<211> 243

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:mAB 17-1A

<400> 4

Met His Gln Thr Ser Met Gly Ile Lys Met Glu Ser Gln Thr Leu Val
 1 5 10 15

Phe Ile Ser Ile Leu Leu Trp Leu Tyr Gly Ala Asp Gly Asn Ile Val
 20 25 30

Met Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly Glu Arg Val
 35 40 45

Thr Leu Thr Cys Lys Ala Ser Glu Asn Val Val Thr Tyr Val Ser Trp
 50 55 60

Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile Tyr Gly Ala
 65 70 75 80

Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser
 85 90 95

Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu
 100 105 110

Ala Asp Tyr His Cys Gly Gln Gly Tyr Ser Tyr Pro Tyr Thr Phe Gly
 115 120 125

Gly Gly Thr Lys Leu Glu Ile Arg Arg Ala Asp Ala Ala Pro Thr Val
 130 135 140

Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser
 145 150 155 160

Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys
 165 170 175

Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp
 180 185 190

Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu
 195 200 205

Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu
 210 215 220

Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg
 225 230 235 240

Asn Glu Cys

<210> 5

<211> 243

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:mAB 17-1A

<400> 5

Met His Gln Thr Ser Met Gly Ile Arg Met Glu Ser Gln Thr Leu Val
 1 5 10 15

Phe Ile Ser Ile Leu Leu Trp Leu Tyr Gly Ala Asp Gly Asn Ile Val
 20 25 30

Met Thr Gln Ser Pro Arg Ser Met Ser Met Ser Val Gly Glu Arg Val
 35 40 45

Thr Leu Thr Cys Arg Ala Ser Glu Asn Val Val Thr Tyr Val Ser Trp
 50 55 60

Tyr Gln Gln Arg Pro Glu Gln Ser Pro Arg Leu Leu Ile Tyr Gly Ala
 65 70 75 80

Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser
 85 90 95

Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala Glu Asp Leu

100	105	110
Ala Asp Tyr His Cys Gly Gln Gly Tyr Ser Tyr Pro Tyr Thr Phe Gly		
115	120	125
Gly Gly Thr Arg Leu Glu Ile Arg Arg Ala Asp Ala Ala Pro Thr Val		
130	135	140
Ser Ile Phe Pro Pro Ser Ser Glu Gln Leu Thr Ser Gly Gly Ala Ser		
145	150	155 160
Val Val Cys Phe Leu Asn Asn Phe Tyr Pro Lys Asp Ile Asn Val Lys		
165	170	175
Trp Lys Ile Asp Gly Ser Glu Arg Gln Asn Gly Val Leu Asn Ser Trp		
180	185	190
Thr Asp Gln Asp Ser Lys Asp Ser Thr Tyr Ser Met Ser Ser Thr Leu		
195	200	205
Thr Leu Thr Lys Asp Glu Tyr Glu Arg His Asn Ser Tyr Thr Cys Glu		
210	215	220
Ala Thr His Lys Thr Ser Thr Ser Pro Ile Val Lys Ser Phe Asn Arg		
225	230	235 240
Asn Glu Cys		